

Themed Section: Orexin Receptors

RESEARCH PAPER

Binding kinetics
differentiates functional
antagonism of orexin-2
receptor ligands

R Mould, J Brown, F H Marshall and C J Langmead*

Heptares Therapeutics Ltd, BioPark, Broadwater Road, Welwyn Garden City, Herts., AL7 3AX,
UK

Correspondence

R Mould, Heptares Therapeutics
Ltd., BioPark, Broadwater Road,
Welwyn Garden City, Herts.,
AL7 3AX, UK. E-mail:
richard.mould@heptares.com*Present address: Monash
Institute of Pharmaceutical
Sciences, Monash University, 381
Royal Parade, Parkville 3052,
Victoria, Australia.

Keywords

orexin; kinetics; equilibrium;
suvorexant; almorexant; EMPA;
association; dissociation; ERK;
inositol phosphate

Received

4 December 2012

Revised

13 March 2013

Accepted

20 March 2013

Orexin receptor antagonism represents a novel approach for the treatment of insomnia that directly targets sleep/wake regulation. Several such compounds have entered into clinical development, including the dual orexin receptor antagonists, suvorexant and almorexant. In this study, we have used equilibrium and kinetic binding studies with the orexin-2 (OX₂) selective antagonist radioligand, [³H]-EMPA, to profile several orexin receptor antagonists. Furthermore, selected compounds were studied in cell-based assays of inositol phosphate accumulation and ERK-1/2 phosphorylation in CHO cells stably expressing the OX₂ receptor that employ different agonist incubation times (30 and 5 min, respectively). EMPA, suvorexant, almorexant and TCS-OX-29 all bind to the OX₂ receptor with moderate to high affinity (pK_i values ≥ 7.5), whereas the primarily OX₁ selective antagonists SB-334867 and SB-408124 displayed low affinity (pK_i values ca. 6). Competition kinetic analysis showed that the compounds displayed a range of dissociation rates from very fast (TCS-OX2-29, k_{off} = 0.22 min⁻¹) to very slow (almorexant, k_{off} = 0.005 min⁻¹). Notably, there was a clear correlation between association rate and affinity. In the cell-based assays, fast-offset antagonists EMPA and TCS-OX2-29 displayed surmountable antagonism of orexin-A agonist activity. However, both suvorexant and particularly almorexant cause concentration-dependent depression in the maximal orexin-A response, a profile that is more evident with a shorter agonist incubation time. Analysis according to a hemi-equilibrium model suggests that antagonist dissociation is slower in a cellular system than in membrane binding; under these conditions, almorexant effectively acts as a pseudo-irreversible antagonist.

LINKED ARTICLES

This article is part of a themed section on Orexin Receptors. To view the other articles in this section visit
<http://dx.doi.org/10.1111/bph.2014.171.issue-2>

Introduction

The family of orexin receptors (also known as hypocretin receptors) belongs to the superfamily of GPCRs. It has two receptor subtypes, known as OX₁ and OX₂; both are known to couple to G_{q/11} leading to increases in intracellular Ca²⁺ concentrations via the activation of phospholipase C (Sakurai *et al.*, 1998). The OX₂ subtype has also been shown to regulate cAMP signalling via activation of both G_s and G_i proteins (Tang *et al.*, 2008).

OX₁ and OX₂ receptors are localized almost exclusively in the brain; OX₁ is most highly expressed in the hypothalamus and locus coeruleus, whereas OX₂ is also predominantly localized within the hypothalamus as well as the cortex. Orexins A and B are the natural peptide hormones for OX₁ and

OX₂. Both are derivatives of prepro-orexin through proteolytic cleavage sharing approximately 50% sequence homology. Orexin-A has been found to be equipotent for OX₁ and OX₂ whereas orexin-B is 10-fold selective for OX₂ over OX₁ (Sakurai *et al.*, 1998). Although initially identified as controlling food intake, it is now widely recognized that the orexinergic system is an important regulator of the arousal state, encompassing feeding behaviour, sleep/wake regulation, reward and regulation of respiration and the cardiovascular system.

Although largely located within the hypothalamus, orexinergic neuronal cell bodies are known to project towards the pituitary (Peyron *et al.*, 1998). Hormone secretions from these glands are known for the role they play in the maintenance of the circadian rhythms. A morning 'surge' in levels of orexin peptides promotes arousal and wakefulness. Levels are

maintained throughout the day but drop off at night during the transition from wakefulness to sleep. Prepro-orexin knock-out (KO) mice show characteristics associated with narcolepsy (Scammell *et al.*, 2000); the disruption of the ability to release these peptides essentially resulting in a disrupted circadian rhythm. Similarly, KO mice lacking orexin receptors also show signs of narcolepsy, an effect that is more pronounced in mice lacking the OX₂ receptor than the OX₁ subtype (Scammell *et al.*, 2000). This evidence highlights the important role of the orexin-signalling pathway, particularly the OX₂ receptor, in the maintenance of the sleep/wake cycle. Furthermore, this system appears to be well conserved across mammalian species, up to and including humans (Wong *et al.*, 2011).

Currently, the main courses of treatment for insomnia are benzodiazepine and 'benzo-like' drugs which act to enhance the effect of neurotransmitter GABA, resulting in sedative, hypnotic and anxiolytic actions, making them commonly used to treat a wide range of disorders aside from insomnia (Durlach *et al.*, 2002). Side effects are also varied, ranging from depression, dependence and sexual dysfunction to more paradoxical aggression and impulsivity; for these reasons, they are only available under prescription and treatments are limited to 4 weeks to avoid addiction. Newer treatments used are drugs such as zolpidem that, although chemically distinct from benzodiazepines, are also positive allosteric modulators of GABA_A receptors and share similar benefits and risks (Wagner *et al.*, 1998). Particularly with respect to insomnia, they share the more acute side effects of disrupting sleep architecture and reducing rapid eye movement as well as producing drowsiness, cognitive deficits and a lack of coordination the morning after administration.

Investigations using the dual orexin receptor antagonists (DORAs), almorexant and suvorexant, show that they act to promote sleep without disrupting the normal circadian rhythm. This has been shown both preclinically and in man (Hoever *et al.*, 2012a,b). This presents a promising more directed approach to treating insomnia than the existing drug therapies. A major hope for orexin receptor antagonists is that they will act more selectively to regulate the sleep/wake cycle (by preventing the drive to stay awake) and lack the general

CNS depressant effects of GABA_A receptor-targeting therapies. Clearly, the duration of action of orexin antagonist hypnotics will depend on both the pharmacokinetics (the rate of clearance from the site of action) and drug-receptor kinetics (the residence time of the antagonist on the orexin receptor). While pharmacokinetics is routinely considered as part of drug discovery, receptor kinetics is only more recently being appreciated as an important component of drug action (Malerczyk *et al.*, 1998; Behm *et al.*, 2010). Examples are mainly found for drug targets requiring slow binding kinetics such as the muscarinic M₃ receptor where antagonists are used to treat chronic obstructive pulmonary disease. Tiotropium was found to have a very long receptor half-life (>12 h) making it suitable for once daily administration via inhalation (Dowling and Charlton, 2006). Another example are atypical antipsychotic drugs used to treat schizophrenia, which act as antagonists of the dopamine D₂ receptor. These vary in their propensity to cause extrapyramidal side effects, an effect which appears to be directly related to the dissociation rate from the receptor; fast dissociating antagonists are more able to equilibrate with synaptic dopamine levels to avoid such adverse effects (Kapur and Seeman, 2001).

In this study, we have used competitive kinetics radioligand binding and cell-based functional assays to investigate the kinetics of binding of orexin-2 receptor antagonists (Figure 1), including the clinically evaluated dual orexin receptor antagonists, almorexant and suvorexant. Binding studies suggest that almorexant and, to a lesser extent, suvorexant, dissociate slowly from the orexin-2 receptor, whereas high affinity antagonists such as EMPA exhibit significantly faster binding kinetics. These observations were supported by cell-based inositol phosphate and ERK-1/2 assays, where slowly dissociating antagonists prevented assays reaching equilibrium, depressing the maximal response to orexin-A and appearing insurmountable under the conditions tested. Furthermore, using an operational model of orthosteric antagonism that is suitable for interrogating competitive ligand-receptor interactions under conditions of hemi-equilibrium, we have demonstrated that it is possible to delineate ligand dissociation rates from functional assay data sets.







					
[³H]-EMPA	TCS-OX2-29	Almorexant	Suvorexant	SB-408124	SB-334867
OX ₂ Selective	OX ₂ Selective	Dual OX ₁ /OX ₂	Dual OX ₁ /OX ₂	OX ₁ Selective	OX ₁ Selective

Figure 1

Chemical structures of compounds tested along with details of selectivity for OX₁ versus OX₂ receptor subtypes. T = tritium.

Methods

Radioligand binding

Cell membranes from HEK293 cells transiently expressing the human OX₂ receptor (Supporting Information) were incubated with [³H]-EMPA in Krebs assay buffer (8.5 mM HEPES, 1.3 mM CaCl₂, 1.2 mM MgSO₄, 118 mM NaCl, 4.7 mM KCl, 4 mM NaHCO₃, 1.2 mM KH₂PO₄, 11 mM glucose, pH 7.4) in a total assay volume of 0.25 mL with a final DMSO concentration of 1%. After 90 min incubation at room temperature, the reaction was terminated by rapid filtration through GF/B 96-well glass fibre plates with 5 × 0.25 mL washes with ddH₂O using a Tomtec cell harvester. Bound radioactivity was determined through liquid scintillation using Lablogic SafeScint and detected on a microbeta liquid scintillation counter. Non-specific binding was determined as that remaining in the presence of a 10 μM saturating concentration of the antagonist EMPA. Saturation studies were carried out by incubating membranes (2 μg protein/well) with a range of concentrations of [³H]-EMPA (0.4 nM–15 nM). Radioligand concentrations were determined using SafeScint and a Beckman LS 6000 liquid scintillation counter. Competition binding was performed incubating membranes (2 μg protein/well) with 1.5 nM concentration of [³H]-EMPA and a range of concentrations of the test compound.

Association kinetics for the radioligand were determined by adding the same cell membrane (2 μg protein/well) to wells containing Krebs buffer with 1% DMSO and 1.5 nM radioligand at various time points up to a total of 3 h. Dissociation kinetics were determined by pre-equilibrating membranes and [³H]-EMPA for 90 min; a saturating concentration of cold EMPA (100 μM) was then added at various time points to prevent re-association of the radioligand as it dissociates from the receptor.

Kinetics of binding of unlabelled compounds was determined using the method of Motulsky and Mahan (1984). In brief, association curves for [³H]-EMPA in the absence or presence of three concentrations of competitive antagonist (typically 0.3, 1 and 3 × K_i value). Association and dissociation rate constants for unlabelled compounds were determined by global analysis of the association data sets, as previously described (Dowling and Charlton, 2006); association and dissociation rate constants for [³H]-EMPA were fixed allowing the model to provide estimates of k_{on} and k_{off} for the test compounds. Ligand-receptor half-lives were calculated as 0.693/k_{off}.

Functional inositol phosphate and ERK1/2 phosphorylation assays

Cell-based inositol phosphate (Cisbio BioAssays, Codolet, France) and ERK1/2 phosphorylation (Surefire, PerkinElmer, Waltham, MA, USA) functional assays were performed in 96-well plates 24 h after seeding with CHO cells stably expressing the human orexin-2 receptor at a density of 25 000 cells/well; full assay details are in the Supporting Information.

Data analysis

For [³H]-EMPA saturation binding studies, data were globally fitted using Prism 5.04 (GraphPad, San Diego, CA, USA) with

a rectangular hyperbola taking into account one site-total and non-specific binding to determine receptor number (B_{max}) and the dissociation rate constant (K_D)

$$Y = \frac{B_{\max} \cdot [A]}{[A] + K_D} + NS \cdot [A]$$

where Y is radioligand binding, B_{max} is the total receptor density, [A] is the radioligand concentration, K_D is the equilibrium dissociation constant of the radioligand and NS is the fraction of non-specific radioligand binding. For radioligand inhibition binding experiments, a one-site binding equation was fitted to the specific binding of each competitive ligand

$$Y = Bottom + \frac{(Top - Bottom)}{1 + 10^{(Log[B] - Log[IC_{50} \cdot n_H])}}$$

where Top and Bottom are the maximal and minimal asymptotes of the curve, respectively, Log[B] is the concentration of competitor, LogIC₅₀ is the logarithm of the concentration of inhibitor that reduces half the maximal radioligand binding for each binding site and n_H is the Hill slope. IC₅₀ values were converted to K_i values (equilibrium dissociation constant) using the equation of Cheng and Prusoff (1973).

Association and dissociation rate constants for [³H]-EMPA binding were determined by global analysis of the association and dissociation binding curves according to mono-exponential association and decay curves to generate estimates of the dissociation (k_{off}) and observed association (k_{obs}) rates for ligand binding; the association rate constant (k_{on}) was determined according to the following relationship

$$k_{obs} = [A] \cdot k_{on} + k_{off}$$

The kinetic equilibrium dissociation constant K_D was calculated as k_{off}/k_{on}; ligand-receptor half-life was calculated as 0.693/k_{off}. For competition kinetics, the [³H]-EMPA curves in the presence and absence of test antagonist, data were fitted to the methods of Motulsky and Mahan (1984) using following equation(s), as described in Dowling and Charlton (2006)

$$K_A = k_1[L] + k_2$$

$$K_B = k_3[I] + k_4$$

$$S = \sqrt{(K_A - K_B)^2 + 4 \cdot k_1 \cdot k_3 \cdot [L] \cdot [I] \cdot 1e^{-18}}$$

$$K_F = 0.5 \cdot (K_A + K_B + S)$$

$$K_S = 0.5 \cdot (K_A + K_B - S)$$

$$Q = \frac{B_{\max} \cdot k_1 \cdot [L] \cdot 1e^{-9}}{K_F - K_S}$$

$$Y = Q \cdot \left(\frac{k_4 \cdot (K_F - K_S)}{K_F \cdot K_S} + \frac{k_4 - K_F}{K_F} e^{(-K_F \cdot t)} - \frac{k_4 - K_S}{K_S} e^{(-K_S \cdot t)} \right)$$

where t is time (min), Y is specific binding, k₁ is the k_{on} value for [³H]-EMPA, k₂ is the k_{off} value for [³H]-EMPA, [L] is the concentration of [³H]-EMPA used (nanomolar), and [I] is the concentration of unlabelled antagonist (nanomolar). Fixing the above parameters allowed the following to be simultaneously calculated: B_{max} is total binding, k₃ is the association rate of unlabelled ligand (M⁻¹·min⁻¹) or k_{on} and k₄ is the dissociation rate of unlabelled ligand (min⁻¹) or k_{off}.

Concentration-response curves to orexin-A were analysed according to the following equation

$$Y = \text{Bottom} + \frac{(\text{Top} - \text{Bottom})}{1 + 10^{(\text{Log}[B] - \text{LogEC}_{50} \cdot n_H)}}$$

where Top and Bottom are the maximal and minimal asymptotes of the curve, respectively, Log[B] is the concentration of competitor, LogEC₅₀ is the logarithm of the concentration of inhibitor that produces a half-maximal response and *n_H* is the Hill slope. Curve-shift data sets for each antagonist in functional assays were analysed according to the same equation with the Bottom and slope parameters shared across all data sets; the value of Top was left to float to determine, if any, the degree of depression of the maximal agonist response.

For antagonists with minimal or no depression in the maximal response, data were fitted according to the following equation

$$Y = \text{Bottom} + \frac{(\text{Top} - \text{Bottom})}{1 + \left(\frac{10^{\text{LogEC}_{50} \left(1 + \frac{[B]}{10^{-pA_2}} \right)^s}}{[A]} \right)^{n_H}}$$

where Top represents the maximal asymptote of the curves, Bottom represents the minimum asymptote of the curves, LogEC₅₀ represents the logarithm of the agonist EC₅₀ in the absence of antagonist, [A] represents the concentration of orexin-A, [B] represents the concentration of the antagonist, *n_H* represents the Hill slope of the agonist curve, *s* represents the Schild slope for the antagonist, and *pA₂* represents the negative logarithm of the concentration of antagonist that shifts the agonist EC₅₀ by a factor of 2. In the absence of antagonist ([B] = 0), this equation becomes the standard four-parameter logistic equation for fitting agonist concentration-response data.

Competitive ligand-receptor interactions in functional assays are traditionally analysed using the method of Arunlakshana and Schild (1959) whereas irreversible antagonism can be quantified using the method of Gaddum *et al.* (1955). However, many functional assays, while profiling competitive antagonists, are run under conditions in which equilibrium may not be reached ('hemi-equilibrium') and as such they depress the maximal agonist response. Accordingly, the functional data for suvorexant and almorexant were fitted according to a combined operational and hemi-equilibrium model for competitive antagonism under non-equilibrium conditions (Kenakin, 2009)

$$\alpha = \frac{[B]/K_B}{([B]/K_B + [A]/K_A + 1)}$$

$$\beta = \frac{[B]/K_B}{([B]/K_B + 1)}$$

$$\gamma = \frac{([B]/K_B + [A]/K_A + 1)}{([A]/K_A + 1)}$$

$$Y = \frac{[A]/K_A (1 - (\alpha \cdot (1 - e^{-k_{off} \cdot \tau \cdot t}) + \beta \cdot e^{-k_{off} \cdot \tau \cdot t})) \cdot \tau \cdot E_m}{[A]/K_A ((1 - (\alpha \cdot (1 - e^{-k_{off} \cdot \tau \cdot t}) + \beta \cdot e^{-k_{off} \cdot \tau \cdot t})) \cdot \tau + 1) + 1}$$

where [A] and [B] represent the concentrations of orexin-A and antagonist, respectively, *K_A* and *K_B* represent the respective equilibrium dissociation constants, *k_{off}* is the dissociation rate constant for the antagonist (min⁻¹), *t* is the assay incubation time (min), *τ* is the operational efficacy of orexin-A

(comprising cell- and agonist-dependent properties) and *E_m* is the maximal system response. All parameters were shared across all data sets except *t* and *E_m*, which were fixed to the assay incubation time, and 100 (if required), respectively. For almorexant, a comparison between a data fits with the *k_{off}* unconstrained and constrained to zero was made using Akaike's Information Criterion (Motulsky and Christopoulos, 2003). In all cases, potency and affinity values were estimated as logarithms (Christopoulos, 1998). Data shown are the mean ± SEM.

Results

Equilibrium [³H]-EMPA binding

Specific binding of [³H]-EMPA represented greater than 95% of total binding and was fully saturable. Non-specific binding was minimal and increased linearly with radioligand concentration (data not shown). [³H]-EMPA bound to the OX₂ receptor with high affinity (*K_D* = 1.4 ± 0.2 nM; *n* = 3) and in a monophasic manner with a maximal binding capacity of 16.5 ± 0.3 pmol mg-protein⁻¹. Ligand depletion at the *K_D* concentration accounted for less than 5% of the total radio-ligand added.

Figure 2 shows the inhibition of [³H]-EMPA binding by a range of orexin receptor antagonists; all antagonists tested fully displaced [³H]-EMPA specific binding. Compounds that are reported to be either dual orexin receptor antagonists or OX₂-selective showed high affinities for the OX₂ receptor, with suvorexant, almorexant, EMPA and TCS-OX2-29 having *pK_i* values of 8.9 ± 0.2, 8.0 ± 0.1, 8.9 ± 0.3 and 7.5 ± 0.4, respectively (Table 1). Compounds which have been reported to be selective for the OX₁ receptor displayed low affinity for the OX₂ receptor with SB-408124 and SB-334867 having *pK_i* values of 6.0 ± 0.2 and 6.1 ± 0.2, respectively (see Table 1).

Kinetic [³H]-EMPA binding

Direct kinetic binding studies indicated that [³H]-EMPA associates rapidly with the OX₂-receptor, reaching equilibrium





Figure 2

Competition for [³H]-EMPA binding to OX₂-expressing HEK293 cell membranes showing the displacement of increasing concentrations by test compounds. Data are representative of at least five independent experiments; error bars show SEM.

Table 1Kinetic binding parameters of various orexin receptor antagonists at the OX₂ receptor (in ascending order of half life)

Antagonist	k_{on} (M ⁻¹ ·min ⁻¹)	k_{off} (min ⁻¹)	$t_{1/2}$ (min)	Kinetic pK _D	Competition pK _I
TCS-OX2-29	$1.6 \pm 0.075 \times 10^6$	0.22 ± 0.026	3.2 ± 0.42	6.9 ± 0.034	7.5 ± 0.20
EMPA ^a	$5.0 \pm 1.7 \times 10^7$	0.094 ± 0.013	7.8 ± 1.0	8.6 ± 0.24	8.9 ± 0.20
SB 334867	$7.5 \pm 6.4 \times 10^3$	0.077 ± 0.065	25 ± 11	5.1 ± 0.22	6.1 ± 0.13
SB 408124	$4.6 \pm 2.2 \times 10^3$	0.017 ± 0.0043	53 ± 13	5.3 ± 0.24	6.0 ± 0.090
Suvorexant	$2.9 \pm 0.34 \times 10^6$	0.012 ± 0.0028	79 ± 20	8.4 ± 0.13	8.9 ± 0.14
Almorexant	$1.1 \pm 0.14 \times 10^6$	0.0050 ± 0.0017	242 ± 138	8.3 ± 0.13	8.0 ± 0.042

^aAll kinetic data were obtained from competition kinetic studies with the exception of [³H]-EMPA that was obtained through direct association and dissociation measurements (Figure 3). Data represent mean $\pm$ SEM of $n \geq$ three independent experiments.

**Figure 3**

Kinetic binding profile of [³H]-EMPA binding to OX₂-expressing HEK293 cell membranes. Association (closed circles) and dissociation (open circles) expressed as percentage of maximum specific binding and globally fit using Prism 5.04. Data are representative of three independent experiments and vertical lines show SEM.

within 30 min; dissociation occurs over a similar time frame when the ligand-receptor complex is exposed to a saturating concentration of unlabelled EMPA (Figure 3). The dissociation rate constant (k_{off}) was estimated to be 0.09 ± 0.01 min⁻¹, leading to a calculated half-life of 7.8 min. Further analysis yielded an estimate for the association rate constant (k_{on}) of $5.0 \pm 1.7 \times 10^7$ M⁻¹·min⁻¹.

In order to determine the binding kinetics of the test antagonists, a competition kinetics method was performed (Motulsky and Mahan, 1984; Dowling and Charlton, 2006). Figure 4 shows the effect of multiple concentrations of unlabelled test compounds on the association binding kinetics of [³H]-EMPA. By fixing the association and dissociation rate constants for [³H]-EMPA to the values previously determined, it was possible to obtain kinetic parameters for binding of the test compounds; these are summarized in Table 1. The rank order of dissociation half-lives for the test compounds was almorexant > suvorexant > SB-408124 > SB-334867 > EMPA > TCS-OX2-29. The varying profiles of the association curves are consistent with those described in Dowling and Charlton (2006), whereby for a competing compound with slower kinetics than [³H]-EMPA, the binding of the rapidly associat-

ing radioligand overshoots the eventual level of equilibrium binding (the final time point of each curve represents what would be detected in a normal equilibrium competition binding assay at each concentration). The difference in profiles for fast and slow binders is best exemplified by TCS-OX2-29 and almorexant, which show a 44-fold difference in estimated dissociation rate (Figure 4; Table 1). It is notable that, despite identical equilibrium binding affinities, EMPA and suvorexant display very different kinetics of binding. In order to verify the kinetic approach, the pK_D values for the test antagonists were calculated as a ratio of estimated k_{off} and k_{on} values; a comparison between these values and the competition pK_I values is shown in Table 1 and Figure 5A. Deming linear regression the two (compared with a line of $y = x$) demonstrates that the two methods of obtaining compound affinities produce comparable results, validating the indirect kinetic method. Interestingly, comparison of the equilibrium binding-derived affinity with both k_{on} (Figure 5B) and k_{off} (Figure 5C) showed that there is a clear correlation between association rate and equilibrium affinity, whereas there appears to be no correlation between affinity and dissociation rate.




Figure 4

Competition kinetics curves for $[^3\text{H}]\text{-EMPA}$ binding to OX_2 -expressing (HEK293) cell membranes in the presence of increasing concentrations of EMPA, TCS-OX2-29, suvorexant and almorexant. Plates were incubated at room temperature for the time points indicated. Data are representative of at least three independent experiments and vertical lines show SEM.




Figure 5

Deming linear correlations between (A) kinetically derived pK_D and pK_I values derived from equilibrium competition binding (slope = 1.2 ± 0.1 ; slope significantly non-zero, $P < 0.01$, extra sum of squares F -test) and (B) $\text{Log } k_{on}$ and equilibrium competition binding pK_I values (slope = 1.3 ± 0.3 ; slope significantly non-zero, $P < 0.01$, extra sum of squares F -test). (C) Lack of correlation of $\text{Log } k_{off}$ and equilibrium competition binding pK_I values. Dotted line shows $y = x$, vertical and horizontal lines show SEM.

phosphorylation assays, which employ 30 min and 5 min agonist incubation times, respectively.

Orexin-A potently stimulated inositol phosphate accumulation in CHO-OX₂ cells, with a $pEC_{50} = 8.4 \pm 0.1$ ($n = 3$; Figure 6). Both TCS-OX2-29 and EMPA caused a concentration-dependent, parallel, rightward shift in the concentration response curve to orexin-A (Figure 6), with minimal effect on the maximum asymptote of the curve (Figures 6 and 8). Schild analysis estimated pA_2 values of 7.4 ± 0.1 and 7.9 ± 0.2 for TCS-OX2-29 and EMPA, respectively, with Schild slope values not significantly different from unity (1.07 ± 0.04 and 1.12 ± 0.08 , respectively; two-tailed T -test: $P = 0.22$ and $P = 0.27$, respectively). These data are consistent with a competitive mechanism of action under equilibrium conditions.

Orexin-A also potently stimulated ERK1/2 phosphorylation in CHO-OX₂ cells, with a $pEC_{50} = 8.9 \pm 0.1$ ($n = 3$; Figure 7). As with the inositol phosphate assay, both TCS-OX2-29 and EMPA caused a concentration-dependent, parallel, rightward shift in the concentration response curve to orexin-A, with minimal effect on the maximum asymptote of the curve (Figures 7 and 8). Schild analysis estimated pA_2 values of 6.7 ± 0.1 and 7.9 ± 0.3 for TCS-OX2-29 and EMPA, respectively, with Schild slope values of 1.12 ± 0.08 and 1.50 ± 0.19 respectively; Supporting Information Fig. S2). Neither of these Schild slope values is significantly different to unity (two-tailed T -test: $P = 0.22$ and $P = 0.12$, respectively), suggestive of a competitive mechanism of action. However, the Schild slope of 1.5 for EMPA may be indicative of inadequate time for the antagonist to re-equilibrate with orexin-A and the receptor, even for a relatively 'fast on-fast off' ligand such as EMPA that does not appear to reduce the maximal agonist response (Kenakin, 2009; Figure 8).

In the inositol phosphate assay, both suvorexant and almorexant also caused a rightward shift in the concentration response curve to orexin-A, but at higher antagonist concentrations the maximal orexin-A response was markedly reduced, particularly for almorexant (Figures 6 and 8). Similar effects on the maximal agonist response were observed in the ERK1/2 phosphorylation assay (Figures 7 and 8). For almorexant in the ERK1/2 assay, there is very little apparent shift in the curve at concentrations that diminish the maximal response. Unsurprisingly, given the reduced amount of time for re-equilibration of antagonist and receptor, a comparison of the two assay formats suggests that the reduction in the maximal response by suvorexant and almorexant is more marked in the ERK1/2 assay than in the inositol phosphate assay (Figure 8).

While it is clear that the slower binding kinetics of suvorexant and almorexant compared to EMPA and TCS-OX2-29

Inositol phosphate accumulation and pERK1/2 assays

In order to determine whether the kinetics of ligand binding had meaningful effects in commonly used cell-based functional assays, the antagonist profile of EMPA, TCS-OX2-29, suvorexant and almorexant versus orexin-A activation was determined in inositol phosphate accumulation and ERK1/2




Figure 6

Effect of increasing concentrations of (A) EMPA, (B) TCS-OX-29, (C) suvorexant and (D) almorexant on orexin-A stimulated inositol phosphate accumulation in CHO-hOX₂ cells. Data were fitted according to a four-parameter logistic equation with values for the minimum asymptote and Hill slopes shared across all of the data sets. Data represent the mean of at least three independent experiments; vertical lines show SEM.

contribute to their diminution of the maximal orexin-A response, we sought to generate an estimates of the dissociation rate constants for these two compounds using an operational model for hemi-equilibrium conditions. For suvorexant, analysis of the grouped data set according to the model provided estimates of Log K_B values of -7.7 and -7.9 in the inositol phosphate and ERK1/2 assays, respectively (Table 2; Supporting Information Figs S1 and S2). The model also provided estimates of the dissociation rate constants (k_{off}), yielding values of 0.00057 min^{-1} and 0.0043 min^{-1} in inositol phosphate and ERK1/2 assays, respectively. Thus, the estimated dissociation rates of suvorexant are approximately three and 21-fold slower than that determined by membrane-based radioligand binding (Table 1, Table 2). For almorexant,

the estimates of Log K_B values were -7.4 and -7.6 in the inositol phosphate and ERK1/2 assays, respectively (Table 2, Supporting Information Figs S1 and S2). However, such was the insurmountable nature of the response that the data were best fitted to a model where k_{off} was constrained to zero, effectively classifying almorexant as an irreversible antagonist in these test systems.

Discussion

Orexin receptor antagonism represents a potentially powerful new approach for the treatment of sleep disorders, effectively targeting the arousal drive in sleep/wake regulation, rather




Figure 7

Effect of increasing concentrations of (A) EMPA, (B) TCS-OX-29, (C) suvorexant and (D) almorexant on orexin-A stimulated ERK1/2 phosphorylation in CHO-hOX₂ cells. Data were fitted according to a four-parameter logistic equation with values for the minimum asymptote and Hill slopes shared across all of the data sets. Data represent the mean of at least three independent experiments; vertical lines show SEM.

than acting as a generalized CNS depressant as is the case with current GABAergic pharmacotherapies. One of the perceived advantages of this approach is by selectively targeting sleep/wake regulation, orexin antagonists will lack some or all of the 'hangover' effects of GABAergic drugs that affect patients the morning following taking the drug. This is predicated on three main assumptions: firstly, that orexin levels increase in the morning to increase arousal and may overcome any residual receptor blockade from the night before; secondly, that the pharmacokinetics of the orexin receptor antagonist are such that receptor occupancy is minimal at the time of waking and thirdly, that the drug-receptor kinetics are such that high receptor occupancy is not prolonged until and beyond the time of waking (even in the absence of drug bathing the receptor).

It is increasingly common to study the kinetics of receptor antagonism as a part of the drug discovery process; drug-receptor kinetics has been shown to be an important factor in drug efficacy (e.g. the CCR5 antagonist, maraviroc; Dorr *et al.*, 2005; Pullen *et al.*, 2006; Jacqmin *et al.*, 2008), duration of action (the muscarinic M₃ receptor antagonist, tiotropium; Dowling and Charlton, 2006) and side-effect profile (second generation atypical antipsychotic drugs; Kapur and Seeman, 2001).

As the orexin-2 receptor has been the main subtype implicated in the efficacy of orexin receptor antagonists, in this study we sought to determine the kinetics of binding of several orexin receptor antagonists, including the clinically profiled dual orexin receptor antagonists suvorexant and almorexant at the orexin-2 receptor. For this, the competition




Figure 8

Comparison of depression of the orexin-A maximal response in (A) ERK1/2 phosphorylation and (B) inositol phosphate accumulation assays as a function of antagonist concentration. Data are taken from fitted maximal asymptotes for each antagonist as shown in Figures 6 and 7.

kinetics method of Motulsky and Mahan (1984) was utilized. Furthermore, the profile of the receptor antagonists was tested in commonly used cell-based functional assays that employ different agonist incubation times (inositol phosphate accumulation and ERK1/2 phosphorylation), potentially making them differentially sensitive to antagonist hemi-equilibrium (Paton and Rang, 1965).

Equilibrium [^3H]-EMPA binding suggests that almorexant, suvorexant and EMPA all bound to the OX_2 receptor with high affinity (pK_i values ≥ 8.0); TCS- OX_2 -29 displayed moderate affinity whereas the mainly OX_1 -selective antagonists, SB-334867 and SB-408124, displayed low affinity for the OX_2 -receptor. Kinetic analysis of the binding of antagonists revealed that there is a clear correlation between the association rate and equilibrium affinity for the compounds tested

(Figure 5B), counter to what is intuitively considered to be the case. Indeed, there appears to be no relationship between dissociation rate and equilibrium affinity; it is notable that EMPA and suvorexant both have the same equilibrium binding affinity but differ in their dissociation rate by nearly 10-fold (Table 1). While this correlation between association rate and affinity is perhaps unusual, it is not unprecedented and has been shown to be the case for β_2 -adrenoceptor agonists (Sykes and Charlton, 2012). However, further studies on larger numbers of compounds across different chemical scaffolds would be required to understand whether this effect is observed for all antagonists of the OX_2 -receptor.

It is clear, however, that there is a range of dissociation rates for binding to the OX_2 receptor, which can differ up to 44-fold. TCS- OX_2 -29, EMPA and both dissociate rapidly from the receptor ($t_{1/2} < 10$ min); however, SB-334867, SB-408124, suvorexant and almorexant display much slower dissociation kinetics with $t_{1/2}$ values of 25, 53, 77 and 242 min, respectively (Table 1). The data for almorexant and EMPA agree well with previous direct kinetic measurements with tritiated versions of the compounds. These showed that EMPA displayed fast dissociation kinetics ($t_{1/2} = 8.9$ min; Malherbe *et al.*, 2009a) and almorexant much slower dissociation kinetics ($t_{1/2} = 105$ min; Malherbe *et al.*, 2009b; $t_{1/2} = 74$ min; Faedo *et al.*, 2012). Furthermore, the kinetic K_D values generated indirectly were in excellent agreement with the K_i values generated by equilibrium competition binding (Figure 5A).

In order to determine whether the differences in kinetics would affect the profile in commonly used cell-based functional assays, the ability of exemplar compounds with fast kinetics (EMPA and TCS- OX_2 -29) and with slow kinetics (suvorexant and almorexant) to antagonize the effects of orexin-A were studied in assays of inositol phosphate accumulation and ERK1/2 phosphorylation at the OX_2 receptor. These assays employed agonist incubation times of 30 and 5 min, respectively. As might be expected, both EMPA and TCS- OX_2 -29 cause surmountable, parallel rightward shifts in the concentration response curve to orexin-A in both inositol phosphate and ERK1/2 phosphorylation assays, with little or no effect on the maximal agonist response (Figures 6–8). Global analysis of the data sets according to the Schild equation yielded pA_2 values in the range 6.7–7.4 for TCS- OX_2 -29 and 7.9 for EMPA (Supporting Information Figs S1 and S2). Although lower than affinity estimates measured by radioligand binding, this is consistent with previous functional affinity estimates for orexin receptor antagonists being lower than those measured by binding approaches (Cox *et al.*, 2010). Notably, the estimated Schild slope values for all the interactions were not significantly different from unity, although for the highest slope value was observed for EMPA-mediated inhibition of orexin-A-induced ERK1/2 phosphorylation (slope = 1.5). Such an observation is potentially indicative with a lack of equilibrium in the assay system (Kenakin, 2009). Thus, even though the antagonism appears surmountable to the naked eye, the short incubation time of the ERK1/2 assay appears to prevent the re-equilibration of even a relatively rapid offset compound such as EMPA with the receptor and agonist.

With this data in mind, it was unsurprising to observe that suvorexant and almorexant, having slower dissociation rates from the OX_2 receptor than EMPA, cause more marked

Table 2

Fitted parameter estimates ($\pm$ fitted standard errors) for grouped data of suvorexant and almorexant-mediated antagonism of orexin-A stimulated inositol phosphate accumulation and ERK1/2 phosphorylation according to an operational hemi-equilibrium model for competitive antagonism (Kenakin, 2009)

	Suvorexant		Almorexant	
	IPOne	pERK1/2	IPOne	pERK1/2
Log K_A	-6.6 ± 0.2	-7.7 ± 0.1	-7.5 ± 0.1	-8.2 ± 0.1
Log K_B	-7.7 ± 0.1	-7.9 ± 0.1	-7.4 ± 0.1	-7.6 ± 0.1
k_{off}^a (min^{-1})	0.00057 ± 0.00043	0.0043 ± 0.0029	$= 0$	$= 0$
$t_{1/2}$ (min)	1215	161	∞	∞
Log τ	1.6 ± 0.2	1.6 ± 0.1	1.1 ± 0.1	0.9 ± 0.1
E_m^b	104	$= 100$	111	$= 100$

^aFor almorexant, comparison of curve fits with k_{off} unconstrained and constrained to zero indicated preference for the latter, hence $t_{1/2} \rightarrow \infty$.

^bFor the ERK1/2 assays the value of E_m was constrained to 100% to aid fitting. Curve fits for these analyses are shown in Figures S1 and S2.

effects on the maximal agonist response in cell-based functional assays. Suvorexant caused a concentration-dependent rightward shift in the orexin-A concentration-response curve in both assay formats with a corresponding 20–30% decrease in the maximal response, an effect particularly evident over the shorter incubation period (Figure 8). However, most notable was almorexant, which produced significant, concentration-dependent depressions in the maximal orexin-A response in both inositol phosphate and ERK1/2 phosphorylation assays with only small effects on the mid-point of the agonist curve. It is clear that the kinetic profile of both antagonists are affecting the nature of the agonist response curve in a manner that it not consistent with surmountable competition.

These data agree with previous observations for almorexant whereby it depressed the maximal orexin-A and -B responses at the OX_2 receptor in manner that the authors described as 'non-competitive' (Malherbe *et al.*, 2009b). It is also consistent with observed responses in functional assays with other orexin receptor antagonists at OX_2 receptor (Faedo *et al.*, 2012).

While the possibility that almorexant is a truly allosteric antagonist of orexin-A at the OX_2 receptor cannot be ruled out on the basis of these data, the competitive nature of the interaction between almorexant and EMPA, itself a competitive antagonist of orexin-A, suggests that this is unlikely. It seems more probable, on the basis of the kinetic data presented, that the profiles observed in both our hands and previously (Malherbe *et al.*, 2009b; Faedo *et al.*, 2012) are due to the lack of equilibrium in the assay(s).

In order to understand better the functional data obtained with suvorexant and almorexant and compare it with the radioligand binding data, an analytical model that describes competitive antagonism under non-equilibrium conditions was utilized (Kenakin, 2009); see Methods for details). This model builds on the operational model (Black and Leff, 1983) and represents an intermediate situation between fully surmountable competition and insurmountable antagonism (such as for an irreversible antagonist), accounting also for receptor reserve (Kenakin, 2009). We

sought to analyse the grouped data from the functional assays to determine estimates of antagonist dissociation rate in the cellular assays. By fixing the assay incubation time, it was possible to generate both estimates of antagonist affinity (Log K_B) and dissociation rate constant (k_{off}). Using this approach, the data for suvorexant yielded Log K_B estimates of -7.7 and -7.9 in inositol phosphate accumulation and ERK1/2 phosphorylation assays, respectively. These values lie between previous estimates of functional affinities at the OX_2 receptor ($K_B = 56$ nM; Cox *et al.*, 2010) and the radioligand binding values reported in this study (Table 1). Interestingly, the assays yielded estimates of the dissociation rate of 0.00057 min^{-1} and 0.0043 min^{-1} for inositol phosphate and ERK1/2 assays, respectively (Table 2). These represent three and 21-fold slower dissociation than measured in the competition kinetic binding method (Table 1). While there is clearly some variability between the two assays (despite being essentially run in similar buffers and environments), it is clear that the dissociation rate for suvorexant in functional cellular systems, as opposed to in membranes, is similar if not slower. For both inositol phosphate and ERK1/2 phosphorylation assays, almorexant data also fitted to the model, yielding affinity estimates (Log K_B) of -7.4 and -7.6 , respectively. These values are in reasonable agreement to the radioligand binding data (Table 1) although slightly less potent than previous functional affinity estimates at the OX_2 receptor [$K_B = 1.5$ nM, (Malherbe *et al.*, 2009b); $IC_{50} = 8$ nM, (Brisbare-Roch *et al.*, 2007)]. However, estimates of the dissociation rate were very small; comparison of the data fits with the value of k_{off} left unconstrained and constrained to zero using Akaike's Information Criterion (Motulsky and Christopoulos, 2003) suggested a preference for the latter. Therefore, as with suvorexant, it seems that the dissociation kinetics in the cellular system are slower even than suggested by the binding studies (Table 1), highlighting the importance of the cellular environment on the response observed. At least in these cellular assays, almorexant appears to be acting as an irreversible antagonist of the OX_2 receptor.

The fact that the two clinical orexin receptor antagonist candidates display the slowest binding kinetics of those com-

pounds tested is interesting and poses further questions for this mechanism of action. It is not uncommon for slow dissociation kinetics for antagonists of peptide receptors to be important or even required for efficacy *in vivo*; CCR5 (Dorr *et al.*, 2005; Jacqmin *et al.*, 2008) and neurokinin NK1 (Lindstrom *et al.*, 2007) are examples of receptors where effectively insurmountable antagonism is important for drug efficacy. Nonetheless, as discussed above, one of the key differentiators for orexin receptor antagonists as therapies for insomnia is the proposed lack of next-day effects. In order to achieve this, prolonged orexin receptor blockade is likely to be undesirable. While pharmacokinetic parameters will dictate the levels of drug bathing the receptor, receptor kinetics may also influence receptor occupancy and pharmacodynamics, especially if the drug-receptor complex has a long half-life (Vauquelin and Van Liefde, 2006). Here, we have demonstrated that different orexin receptor antagonists display highly divergent dissociation binding kinetics that are not correlated with equilibrium binding affinity. Furthermore, dissociation rates appear to be even slower in a functional cellular assay environment than in simple membrane-based binding assays. Taken together, these data indicate that it may be important to consider the binding kinetics of orexin receptor antagonists as part of the drug discovery process.

Conflict of interest

None of the authors listed have any conflicts of interest regarding the subject matter of this paper and any claims made. The authors are all employed or have been employed by Heptares Therapeutics, a company that has carried out research into orexin antagonists in the past and is likely to continue into the future.

References

- Arunlakshana O, Schild HO (1959). Some quantitative uses of drug antagonists. *Br J Pharmacol* 14: 48–58.
- Behm DJ, Aiyar NV, Olzinski AR, McAtee JJ, Hilfiker MA, Dodson JW *et al.* (2010). GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity *ex vivo*. *Br J Pharmacol* 161: 207–228.
- Black JW, Leff P (1983). Operational models of pharmacological agonism. *Proc R Soc Lond B Biol Sci* 220: 141–162.
- Brisbare-Roch C, Dingemans J, Koberstein R, Hoeber P, Aissaoui H, Flores S *et al.* (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans. *Nat Med* 13: 150–155.
- Cheng Y, Prusoff WH (1973). Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction. *Biochem Pharmacol* 22: 3099–3108.
- Christopoulos A (1998). Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. *Trends Pharmacol Sci* 19: 351–357.
- Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ *et al.* (2010). Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. *J Med Chem* 53: 5320–5332.
- Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M *et al.* (2005). Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. *Antimicrob Agents Chemother* 49: 4721–4732.
- Dowling MR, Charlton SJ (2006). Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor. *Br J Pharmacol* 148: 927–937.
- Durlach J, Pages N, Bac P, Bara M, Guet-Bara A (2002). Biorhythms and possible central regulation of magnesium status, phototherapy, darkness therapy and chronopathological forms of magnesium depletion. *Magn Res* 15: 49–66.
- Faedo S, Perdoni E, Antolini M, Di Fabio R, Merlo Pich E, Corsi M (2012). Functional and binding kinetic studies make a distinction between OX1 and OX2 orexin receptor antagonists. *Eur J Pharmacol* 692: 1–9.
- Gaddum JH, Hameed KA, Hathway DE, Stephens FF (1955). Quantitative studies of antagonists for 5-hydroxytryptamine. *Q J Exp Physiol* 40: 49–74.
- Hoeber P, de Haas SL, Dorffner G, Chiossi E, van Gerven JM, Dingemans J (2012a). Orexin receptor antagonism: an ascending multiple-dose study with almorexant. *J Psychopharmacol* 26: 1071–1080.
- Hoeber P, Dorffner G, Benes H, Penzel T, Danker-Hopfe H, Barbano MJ *et al.* (2012b). Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. *Clin Pharmacol Ther* 91: 975–985.
- Jacqmin P, McFadyen L, Wade JR (2008). A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc. *Br J Clin Pharmacol* 65 (Suppl. 1): 95–106.
- Kapur S, Seeman P (2001). Does fast dissociation from the dopamine D_2 receptor explain the action of atypical antipsychotics?: a new hypothesis. *Am J Psychiatry* 158: 360–369.
- Kenakin TP (2009). Orthosteric drug antagonism. In: Kenakin T (ed.). *A Pharmacology Primer*, 3rd edn. Elsevier Academic Press: London, pp. 105–127.
- Lindstrom E, von Mentzer B, Pahlman I, Ahlstedt I, Uvebrant A, Kristensson E *et al.* (2007). Neurokinin 1 receptor antagonists: correlation between *in vitro* receptor interaction and *in vivo* efficacy. *J Pharmacol Exp Ther* 322: 1286–1293.
- Malerczyk C, Fuchs B, Belz GG, Roll S, Butzer R, Breithaupt-Grogler K *et al.* (1998). Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man. *Br J Clin Pharmacol* 45: 567–573.
- Malherbe P, Borroni E, Gobbi L, Knust H, Nettekoven M, Pinard E *et al.* (2009a). Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. *Br J Pharmacol* 156: 1326–1341.
- Malherbe P, Borroni E, Pinard E, Wettstein JG, Knoflach F (2009b). Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists. *Mol Pharmacol* 76: 618–631.

Motulsky HJ, Christopoulos A (2003). Comparing models using Akaike's Information Criterion (AIC). In: *Fitting Models to Biological Data Using Linear and Nonlinear Regression*. GraphPad: San Diego, CA, pp. 43–48.

Motulsky HJ, Mahan LC (1984). The kinetics of competitive radioligand binding predicted by the law of mass action. *Mol Pharmacol* 25: 1–9.

Paton WD, Rang HP (1965). The uptake of atropine and related drugs by intestinal smooth muscle of the guinea-pig in relation to acetylcholine receptors. *Proc R Soc Lond B Biol Sci* 163: 1–44.

Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG *et al.* (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems. *J Neurosci* 18: 9996–10015.

Pullen S, Sale H, Napier C, Mansfield R, Holbrook M (2006). Maraviroc is a slowly reversible antagonist at the human CCR5 in a CRE luciferase reporter gene assay (abstract 504). 13th Conference on Retroviruses and Opportunistic Infections; 2006 February 5–8; Denver, CO.

Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H *et al.* (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 92: 573–585.

Scammell TE, Estabrooke IV, McCarthy MT, Chemelli RM, Yanagisawa M, Miller MS *et al.* (2000). Hypothalamic arousal regions are activated during modafinil-induced wakefulness. *J Neurosci* 20: 8620–8628.

Sykes DA, Charlton SJ (2012). Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting beta2-adrenoceptor agonists. *Br J Pharmacol* 165: 2672–2683.

Tang J, Chen J, Ramanjaneya M, Punnett A, Conner AC, Rande HS (2008). The signalling profile of recombinant human orexin-2 receptor. *Cell Signal* 20: 1651–1661.

Vauquelin G, Van Liefde I (2006). Slow antagonist dissociation and long-lasting in vivo receptor protection. *Trends Pharmacol Sci* 27: 356–359.

Wagner J, Wagner ML, Henning WA (1998). Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. *Ann Pharmacother* 32: 680–691.

Wong KK, Ng SY, Lee LT, Ng HK, Chow BK (2011). Orexins and their receptors from fish to mammals: a comparative approach. *Gen Comp Endocrinol* 171: 124–130.

Supporting information

Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

<http://dx.doi.org/10.1111/bph.12245>

Figure S1 Effect of increasing concentrations of (a) EMPA, (b) TCS-OX-29, (c) suvorexant and (d) almorexant on orexin-A stimulated inositol phosphate accumulation in CHO-hOX₂ cells. Grouped data were fitted globally according to the Schild equation for EMPA and TCS-OX2-29 and according to the operational hemi-equilibrium model for suvorexant and almorexant (as detailed in Methods).

Figure S2 Effect of increasing concentrations of (a) EMPA, (b) TCS-OX-29, (c) suvorexant and (d) almorexant on orexin-A stimulated ERK1/2 phosphorylation in CHO-hOX₂ cells. Grouped data were fitted globally according to the Schild equation for EMPA and TCS-OX2-29 and according to the operational hemi-equilibrium model for suvorexant and almorexant (as detailed in Methods).